P53 expression in various types of hydropic placentas (through ploidy analysis as a complementary tool in diagnosis of samples) by Khooei, Alireza et al.
Caspian J Intern Med 2019; 10(2):205-210  
DOI: 10.22088/cjim.10.2.205 
    Original Article 
 
 
 
 
 
 
Alireza Khooei (MD) 1 
Fatemeh Atabaki Pasdar (PhD) 2* 
Alireza Fazel (PhD) 2 
Mahmoud Mahmoudi (PhD) 3 
Mohammad Reza Nikravesh 
(PhD) 4  
Shahrzad Daneshmand 
Shahbazian (BSc) 5 
 
 
 
1. Department of Pathology, Emam 
Reza Hospital, Mashhad University 
of Medical Sciences, Mashhad, Iran 
2. Department of Anatomical 
Sciences, Faculty of Medicine, 
Urmia University of Medical 
Sciences, Urmia 
3. Immunology Research Center, 
Bu Ali Research Institute, Mashhad 
University of Medical Sciences, 
Mashhad, Iran 
4. Department of Anatomy and Cell 
Biology, faculty of Medicine, 
Mashhad University of Medical 
Sciences, Mashhad, Iran 
5. Department of Biomedical 
Engineering, School of Electrical 
Engineering, Iran University of 
Science & Technology (IUST), 
Tehran, Iran 
 
 
  
* Correspondence: 
Fatemeh Atabaki Pasdar, 
Department of Anatomical 
Sciences, Faculty of Medicine, 
Urmia University of Medical 
Sciences, Urmia, Iran 
 
 
E-mail: f_atabak@yahoo.com 
Tel: 0098 4432770397 
Fax: 0098 4432780800 
 
 
 
 
 
Received: 7 Aug 2018  
Revised: 17 Dec 2018 
Accepted: 20 Dec 2018 
 
P53 expression in various types of hydropic placentas 
(through ploidy analysis as a complementary tool in 
diagnosis of samples) 
 
Abstract 
Background: Placentas characterized by hydropic swelling of chorionic villi occur in a 
spectrum of pathological conditions including hydropic abortion (HA), partial 
hydatidiform mole (PHM) and complete hydatidiform mole (CHM). The purpose of this 
study was to investigate whether the expression of p53 tumour suppressor protein could 
differentiate these various types of hydropic placentas. 
Methods: p53 immunohistochemical staining was performed in 19 molar (8 PHM and 11 
CHM) and 10 non-molar (HA) formalin-fixed, paraffin-embedded tissue samples. Ploidy 
analysis using flow cytometry was performed as a complementary tool in diagnosis of 
samples. 
Results: DNA histograms obtained from all samples had confirmed diploidy in HAs and 
CHMs and triploidy in PHMs. p53 immunoreactivity was assessed in villous 
cytotrophoblasts, syncytiotrophoblasts and stromal cells. The p53 positive reaction was 
predominantly observed in the nuclei of cytotrophoblastic cells and rarely in stromal cells, 
no reaction was seen in syncytiotrophoblasts. The mean percentage of p53 positive cells 
were 6.10±3.75 for HA, 25.87±13.4 for PHM and 39.83±18.76 for CHM.  There was a 
significant difference in P53 immunoreactivity of cytotrophoblastic cells between CHM 
and HA (P<0.001), and between PHM and HA (P=0.004). There was no significant 
difference in immunohistochemical reactivity between CHM and PHM (P=0.068). 
Conclusion: This study confirms that p53 immunostaining may be helpful in 
distinguishing complete and partial hydatidiform mole from hydropic abortion, but not 
complete hydatidiform mole from partial hydatidiform mole. 
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Gestational trophoblastic disease (GTD) comprises a group of disorders that arise 
from placental trophoblastic tissue after abnormal fertilization and may follow a 
hydatidiform mole (HM) or a nonmolar pregnancy. These disorders include premalignant 
and malignant conditions. HMs represent premalignant condition. The malignant form of 
the disease is known as gestational trophoblastic neoplasia (GTN). GTN is comprised of 
four histologic subtypes: invasive mole, choriocarcinoma, epithelioid trophoblastic tumor 
and placental-site trophoblastic tumor (1, 2). HM or molar pregnancy is the most common 
form of GTD; this includes both partial hydatidiform mole (PHM) and complete 
hydatidiform mole (CHM). The importance of such a condition derives from its potential 
for persistent trophoblastic disease or GTN (3). The incidence of molar pregnancy varies 
geographically, being highest in Asian countries (4). 
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HM is an abnormal pregnancy characterized by hydropic 
swelling of placental villi and trophoblastic hyperplasia (5),
 
Placentas characterized by hydropic swelling of chorionic 
villi occur in a spectrum of pathologic conditions including 
hydropic abortion (HA), partial hydatidiform mole, and 
complete hydatidiform mole. Degenerative changes in a 
nonmolar placenta (so-called "hydropic abortion") is a 
phenomenon where numerous cystic spaces are formed 
within the placenta which is often accompanied by placental 
enlargement. It can occur in a first trimester pregnancy loss. 
In this situation the serum beta HCG tended to be low and 
would show a decline. Sonographic appearances can 
sometimes mimic gestational trophoblastic disease (6). 
Accurate diagnostic classification of hydropic placentas 
is important as the risk of persistent gestational trophoblastic 
diseases or GTN is different among the three entities (7). 
Whereas hydropic abortion is completely benign, 
hydatidiform moles have a significant risk for developing 
persistent gestational trophoblastic disease, with a higher 
incidence in patients with complete hydatidiform mole (10-
30%) than in patients with partial hydatidiform mole (0.5-
5%) (8). Histologic examination is the main tool in the 
diagnosis of molar pregnancies. However, there is 
considerable overlap in the histologic features between molar 
and non-molar pregnancies and between complete 
hydatidiform mole (CHM) and partial hydatidiform mole 
(PHM), resulting in significant inter-observer and intra-
observer variability in the diagnosis (9, 10). Recently, 
pathologists have relied on molecular techniques, such as 
DNA flow cytometry, chromosome in situ hybridization, and 
polymerase chain reaction-based genotyping or HLA typing, 
which by showing DNA content differences, help to 
correctly identify the hydropic placentas (11). However, the 
molecular methods are technically difficult, relatively 
expensive and time consuming. Notably, the 
immunoistochemistry (IHC) plays a very important role in 
the differential diagnosis between molar disease and non-
molar abortions (12). It was evident that gestational 
trophoblastic disease exhibits an increased apoptotic activity 
when compared with non-molar placentas (13), moreover, 
apoptosis appears to be related closely to the risk of GTN 
after CHM. It has been found that a low apoptotic index is 
associated with a higher risk of GTN (14).  
P53 is known as a tumor suppressor gene which encodes 
a nuclear phosphoprotein and its mutation seems to be 
involved in many human cancer pathogenesis (15). The 
tumor-suppressor protein p53 is an important inducer of 
apoptosis (16). Several studies have revealed that 
overexpression of p53 is involved in the pathogenesis of 
GTD (17, 18). The present study was carried out to evaluate 
the expression pattern of p53 in HAs, PHMs and CHMs, and 
to assess the value of this marker in differential diagnosis of 
the three entities. 
 
 
Methods 
Case Selection: Formalin-fixed, paraffin-embedded 
gestational products from 29 patients, including 11 complete 
hydatidiform moles, 8 partial hydatidiform moles and 10 
hydropic spontaneous abortions diagnosed in the Emam 
Reza and Qhaem Departments of pathology, affiliated to 
Mashhad University of Medical Sciences, were gathered. 
The present study has been approved by the Ethics 
Committee of Mashhad University of Medical Sciences. 
Tissue sections of the specimens were stained with 
routine hematoxylin-eosin and histopathologically reviewed 
by the pathologist using published criteria (19), Diagnosis of  
three entities was confirmed by ploidy analysis using flow 
cytometry in all samples and confirmed diploidy in 
spontaneous abortions and complete moles, and triploidy in 
partial moles (20). 
Flow Cytometry: Flow cytometric DNA analysis was 
performed on formalin-fixed, paraffin-embedded tissue 
blocks. The selection criterion for the blocks was the 
presence of both placental and maternal (decidual) tissue in 
approximately such amounts that representative DNA 
histograms could be anticipated. Maternal tissue had to be 
present as the internal diploid control. One 50 μm section of 
each block was placed in 10 ml glass centrifuge tubes and 
dewaxed using two changes of xylene, 3 ml for 10 min at 
room temperature, and then rehydrated in a sequence of 3 ml 
of 100%, 95%, 75%, and 50% ethanol for 10 min each at 
room temperature with centrifugation and decantation of the 
supernatant after each step. The tissues were then washed 
twice in distilled water and re-suspended in pepsin solution 
(1 mL of 0.05% pepsin in 0.9% NaCl, pH 1.5) at 37°C for 
45-60 minutes with intermittent mixing using a vortex. The 
reaction was stopped with cold PBS and the samples were 
washed twice with phosphate buffered saline (PBS).The 
resulting cell suspension was washed twice with PBS. After 
addition of RNase to remove any nuclear or residual 
cytoplasmic RNA, and propidium iodide, ploidy was 
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determined by flow cytometry using facscalibur flow 
cytometer (Becton-Dickinson). The data were analyzed with 
use of the computer program Lysys II Software (Becton-
Dickinson, Mountain View, CA, USA) (20). 
Immunohistochemistry: 5μm thick sections were cut and 
incubated for 60 min at 60ºC, then the sections were 
deparaffinized in xylene and rehydrated in a descending 
ethanol series. Endogenous peroxidase activity was blocked 
by a 20 minute treatment with three percent hydrogen 
peroxidase in phosphate-buffered saline (PBS). The slides 
were then washed twice in PBS, pH 7.4 and subsequently 
transferred to retrieval buffer (10-Mm sodium citrate buffer, 
pH 6.0) and heated in a microwave oven (at a power of 700 
W). The slides were left to cool at room temperature, then 
were incubated with mouse monoclonal antibody for 30 min 
at room temperature (p53: prediluted (ready to use), Clone 
DO-7, N1581, Dako, Glostrup, Denmark). Later the sections 
were rinsed in PBS and incubated with polymer-based 
Envision (Dako Cytomation, Glostrup, Denmark). The 
chromogenic reaction was performed by 3, 3-
diaminobenzidine (DAB), (Dako Cytomation, Glostrup, 
Denmark). The sections were then counterstained with 
Mayer ̛s hematoxylin. The sections of colon cancer were used 
as a positive control for p53, and negative controls were 
stained by skipping primary antibody incubation (21, 22). 
Evaluation of protein expression was carried out. All 
immunostained sections were independently examined by 
the same two observers with a ×400 objective under the light 
microscope (Olympus BX-51, Olympus, Tokyo, Japan), 
while they did not know about the slide diagnosis, therefore 
the analysis was double-blind. A staining is considered 
positive, when the cells show a positive nuclear staining, 
immunoexpression analyses for villous cytotrophoblasts, 
syncytiotrophoblasts and stromal cells, commenced from the 
field with most staining, separately by counting 100 cells of 
each population per slide, (23, 24). 
        
 
 
 
 
 
 
 
 
Fig. 1a 
     
 
 
 
 
 
 
 
 
 
Fig. 1b 
Figure 1. Examples of the two kinds of DNA histograms. 
Vertical axis, number of counted events; horizontal axis, 
channel number, representing the relative DNA content. 
(a) Normal diploid DNA histogram. One high peak is 
considered to be diploid maternal and placental cell 
populations. (b) DNA histogram expressing triploidy.  
 
The first peak represents maternal diploid cells and the 
second peak represents placental cells with a triploid DNA 
content (20). Statistical analyses were conducted using 
Kolmogorov-Smirnov, ANOVA and Tukey’s HSD tests. The 
results were expressed as mean±SD. The differences were 
considered statistically significant at a p-value less than 0.05. 
All statistical tests were performed using SPSS software. 
 
 
Results 
DNA histograms were obtained from all samples. 
Examples of the DNA histograms expressing diploidy in 
spontaneous abortions and complete moles and triploidy in 
partial moles are shown in (fig.1a-b). p53 immunoreactivity 
was assessed in villous cytotrophoblasts, 
syncytiotrophoblasts and stromal cells. Positive cells were 
found to be restricted mostly to the villous cytotrophoblasts, 
while syncytiotrophoblasts showed an absence of 
immunostaining for p53, and occasional weak nuclear 
staining was seen in the stromal cells (fig. 2a-c). The 
percentage of p53 positive cells are shown in (fig. 3). There 
was a significant difference in p53 immunoreactivity with 
cytotrophoblastic cells between complete hydatidiform 
moles and hydropic abortions and also between partial 
hydatidiform moles and hydropic abortions,  There was no 
significant difference in immunohistochemical reactivity 
between CHM and PHM (P=0.068). The results of statistical 
analyses are summarized in (table 1). 
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Table 1. Results of statistical analysis to compare p53 
expression between groups 
Groups PHM, HA CHM, HA   CHM, PHM 
P.Value   P=0.004   P<0.001             P=0.068 
CHM: Complete Hydatidiform Mole;    PHM: Partial Hydatidiform Mole;          
HA: Hydropic Abortion 
 
       
 
 
 
 
 
 
 
 
 
Fig. 2a 
  
 
 
 
 
 
 
 
 
 
 
Fig. 2b 
 
 
 
 
 
 
 
 
 
 
Fig. 2c 
Figure 2. Immunoreactivity with p53 in partial 
hydatidiform mole (a), complete hydatidiform mole (b) 
and hydropic abortion (c), which confined to the nuclei of 
cytotrophoblasts. (arrow), (counterstained with Mayer ̛s 
hematoxylin original magnification x 400) 
 
                  
 
 
 
 
 
 
 
 
Figure 3. The percentage of p53 positive cells in various 
groups (Mean±SD) 
 
Discussion 
About 50% of GTN follows molar pregnancy (25), 
whereas hydropic abortion is completely benign (8). The 
histologic separation of hydropic abortions from partial 
moles and of partial moles from complete moles may be 
difficult. Although diagnostic criteria are established, there is 
considerable intra and inter-observer variability when using 
gross and microscopic findings alone (9, 10). Studies have 
recently shown that immunohistochemistry for various 
markers is useful for confirming the diagnosis and is a 
complementary method to pathologic interpretation (26). 
The value of immunohistochemical analysis of paternally 
imprinted, maternally expressed p57 gene for improving the 
diagnosis of hydatidiform moles has been demonstrated in a 
number of recent studies (27, 28). However, p57 
immunohistochemistry can identify complete hydatidiform 
moles (androgenetic diploidy) by the lack of p57 expression 
but cannot distinguish partial hydatidiform moles (diandric 
monogynic triploidy) from non-molar (biparental diploidy) 
specimens. The tumour suppressor p53 plays a central role in 
protection against DNA damage, uncontrolled proliferation 
and neoplastic transformation, primarily by inducing cell 
cycle arrest or apoptosis (29).  
In this study, p53 immunohistochemical staining was 
performed in 19 molar (8 PHM and 11 CHM) and 10 non-
molar (HA) formalin-fixed, paraffin-embedded tissue 
samples to assess the value of this marker in differential 
diagnosis of these three entities. The p53 positive reaction 
was predominantly observed in the nuclei of 
cytotrophoblastic cells and rarely in stromal cells, while 
syncytiotrophoblasts showed an absence of 
immunolocalization. This is consistent with previous studies 
performed by Qiao et al. (30), Halperin et al. (31) and kale et 
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al. (16). Cytotrophoblast is the trophoblastic stem cell, 
whereas syncytiotrophoblast is the terminally differentiated 
cell (32),
 
therefore p53 may be an indicator of proliferative 
activity. Based on the data, obtained in the present study, 
there was a significant difference in P53 immunoreactivity of 
cytotrophoblastic cells between CHM and HA and between 
PHM and HA, although there was a difference between 
CHM and PHM, but this did not reach statistical 
significance. This is consistent with previous studies 
performed by Kheradmand et al. (33) and Al-Bozom et al. 
(34). It has been reported that p53 gene mutation is rare in 
complete hydatidiform mole and trophoblastic tumours (31, 
35). Cheung et al. reported a positive correlation between 
p53 and Ki-67 proliferation index in trophoblastic tissues of 
hydatidiform moles (36). Hence, p53 overexpression may be 
a reflection of the higher proliferation capacity of the 
trophoblastic cells in molar tissues. A possible role of 
expression of the p53 protein in proliferative trophoblastic 
tissues is an attempt to modulate the excessive proliferative 
activity in trophoblastic cells (37). On the other hand, 
Halperin et al. evaluated the expression of the p53 and 
apoptosis in GTD and normal placenta and showed that the 
percentage of apoptotic cells demonstrated a significant 
increase in HMs compared with normal placenta and also 
significant overexpression of p53 in HMs compared with 
normal placenta, they concluded that p53 overexpression in 
hydatidiform moles could be the result of upregulation of 
apoptosis (31). A recent study reported significantly higher 
p53 expression in CHMs compared with the PHMs and HAs 
(26), whereas based on our findings, although there was a 
difference between CHMs and PHMs, this did not reach the 
statistical significance. This discrepancy may be due to the 
use of different antibody clones or retrieval methods, 
furthermore, in our study ploidy analysis using flow 
cytometry was performed for the confirmation of the 
histologic diagnosis of samples.  
In conclusion, this study confirms that p53 
immunostaining may be helpful in distinguishing complete 
and partial hydatidiform mole from hydropic abortion, but 
not complete hydatidiform mole from partial hydatidiform 
mole. 
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